Therapy Areas: Central Nervous System
Kite reveals data from ZUMA-1 Yescarta trial
10 December 2019 -

Kite, a Gilead Company, has revealed new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma at the 61st American Society of Hematology Annual Meeting & Exposition, in Orlando from December 7–10, 2019, it was reported yesterday.

These results included updated overall survival data from the pivotal phase two study after three years following a single infusion of Yescarta and an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events.

The United States Food and Drug Administration (FDA) has approved the product as the first CAR T cell therapy intended for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. It is not indicated for the treatment of patients with primary central nervous system lymphoma.